In in vivo xenograft models, 24 days of doxorubicin (50 ng/mL) treatment lead to growth inhibition (tumour sizes were reduced by about 50%; the average tumour weight of the controls was 0.638 ± 0.075 g; the average tumour weight of the doxorubicin-treated group was 0.375 ± 0.107 g; the increases in tumour volumes are given in Figure S2) and almost similar metabolic changes; slightly increased mTORC1, ACSS2 protein levels and, in parallel, decreased levels of other metabolic enzymes were observed using IHC analyses. The gene discussed is ACSS2; the disease is neoplasm.